These waveform features provide complementary measures of altered neural processing. Comparing amplitude, latency, and the timing of ERP components across treatment conditions can show whether a drug changes the strength or temporal pattern of brain responses. In pharmacology, this supports more detailed interpretation of effects on attention, perception, cognition, and sensory processing than a single overall waveform description.
Stimulus-aligned epochs place EEG activity in a common temporal frame, allowing responses associated with the same event to be compared. Averaging these segments reduces background noise and makes consistent event-related activity easier to characterize. This processing is important because the resulting waveform features provide a clearer basis for evaluating treatment-related changes in neural responses.
ERP measures can identify changes in neural processing even when behavioral performance appears similar between treatment conditions. A drug may alter the timing, amplitude, or component pattern of an event-related response without producing an obvious behavioral difference. This makes ERP comparisons useful for detecting pharmacological effects on attention, perception, cognition, or sensory processing that behavior alone may miss.
The workflow begins by recording electroencephalographic activity during a stimulus or event. Researchers then segment the continuous recording into epochs aligned with that event, average the segments to reduce background noise, and characterize the resulting waveform. Measurements of amplitude, latency, and component timing can then be compared across treatment conditions to assess drug-related changes.
Researchers can use this approach when they need objective measures of how a drug affects central nervous system activity or specific forms of neural processing. Studies may examine attention, perception, cognition, or sensory processing and compare responses across treatment conditions. The method is particularly useful when behavioral results do not fully reveal the drug’s effects.
Treatment-related waveform differences can provide information about how drugs influence event-related neural processing and may help investigate central nervous system mechanisms. Because ERP measures quantify changes in brain responses, they can also support evaluation of potential biomarkers of response. Their value comes from linking pharmacological conditions with measurable changes in neural activity.